- Home
- KPTI vs SRV Comparison
KPTI vs SRV Comparison
Compare KPTI & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- SRV
- Stock Information
- Founded
- KPTI 2008
- SRV 2007
- Country
- KPTI United States
- SRV United States
- Employees
- KPTI N/A
- SRV N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- SRV Finance Companies
- Sector
- KPTI Health Care
- SRV Finance
- Exchange
- KPTI Nasdaq
- SRV Nasdaq
- Market Cap
- KPTI 121.2M
- SRV 125.6M
- IPO Year
- KPTI 2013
- SRV N/A
- Fundamental
- Price
- KPTI $0.83
- SRV $47.13
- Analyst Decision
- KPTI Strong Buy
- SRV
- Analyst Count
- KPTI 4
- SRV 0
- Target Price
- KPTI $5.00
- SRV N/A
- AVG Volume (30 Days)
- KPTI 906.2K
- SRV 33.9K
- Earning Date
- KPTI 10-31-2024
- SRV 01-01-0001
- Dividend Yield
- KPTI N/A
- SRV 13.38%
- EPS Growth
- KPTI N/A
- SRV N/A
- EPS
- KPTI N/A
- SRV N/A
- Revenue
- KPTI $145,668,000.00
- SRV N/A
- Revenue This Year
- KPTI $6.41
- SRV N/A
- Revenue Next Year
- KPTI $11.85
- SRV N/A
- P/E Ratio
- KPTI N/A
- SRV N/A
- Revenue Growth
- KPTI N/A
- SRV N/A
- 52 Week Low
- KPTI $0.62
- SRV $30.73
- 52 Week High
- KPTI $1.95
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- KPTI 57.02
- SRV 78.36
- Support Level
- KPTI $0.71
- SRV $45.52
- Resistance Level
- KPTI $0.94
- SRV $47.01
- Average True Range (ATR)
- KPTI 0.07
- SRV 0.67
- MACD
- KPTI 0.02
- SRV 0.21
- Stochastic Oscillator
- KPTI 64.26
- SRV 95.51
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.